The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Stukan A.I.

Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar, Russia

Murashko R.A.

Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar, Russia

Bodnya V.N.

Department of Oncology with Course of Thoracic Surgery, Faculty for Postgraduate Training and Professional Retraining of Specialists, Kuban State Medical University, Ministry of Health of Russia, Krasnodar, Russia

Makarova Yu.M.

Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar, Russia

Vasilenko I.N.

Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar, Russia

Topical issues of chemoradiotherapy for oropharyngeal squamous cell carcinoma: the efficiency and toxicity of chemotherapy regimens with the goal of radiomodification

Authors:

Stukan A.I., Murashko R.A., Bodnya V.N., Makarova Yu.M., Vasilenko I.N.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2018;7(3): 61‑67

DOI: 10.17116/onkolog20187361

Read: 2613 times

Download PDF (RU)
Contact the author
Table of contents

TOPICAL ISSUES OF CHEMORADIOTHERAPY FOR OROPHARYNGEAL SQUAMOUS CELL CARCINOMA: THE EFFICIENCY AND TOXICITY OF CHEMOTHERAPY REGIMENS WITH THE GOAL OF RADIOMODIFICATION
TOPICAL ISSUES OF CHEMORADIOTHERAPY FOR OROPHARYNGEAL SQUAMOUS CELL CARCINOMA: THE EFFICIENCY AND TOXICITY OF CHEMOTHERAPY REGIMENS WITH THE GOAL OF RADIOMODIFICATION

To cite this article:

Stukan AI, Murashko RA, Bodnya VN, Makarova YuM, Vasilenko IN. Topical issues of chemoradiotherapy for oropharyngeal squamous cell carcinoma: the efficiency and toxicity of chemotherapy regimens with the goal of radiomodification. P.A. Herzen Journal of Oncology. 2018;7(3):61‑67. (In Russ.)
https://doi.org/10.17116/onkolog20187361

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The review discusses chemoradiotherapy, induction chemotherapy, and adjuvant chemotherapy for oropharyngeal squamous cell carcinoma. It considers the efficiency and toxicity of chemotherapy regimens with the goal of radiomodification. Concurrent high-dose cisplatin chemotherapy is indicated for patients with stage IV and T3N0—1 oropharyngeal squamous cell carcinoma who receive radical radiotherapy. Patients receiving adjuvant radiotherapy after surgical treatment in the presence of positive resection margins should undergo concurrent chemoradiotherapy using an intermittent high-dose cisplatin chemotherapy regimen. If there are contraindications to the use of high-dose cisplatin, routine adjuvant systemic chemotherapy is not recommended. Induction chemotherapy is not indicated for patients with oropharyngeal squamous cell carcinoma either. The data of multicenter randomized trials indicate that chemoradiotherapy improves locoregional control and overall survival rates in patients with oropharyngeal squamous cell carcinoma. To achieve regional control of the disease and overall survival benefits after concurrent chemoradiotherapy, it is necessary to administer cisplatin to a cumulative dose of 200—250 mg/m2. Concurrent weekly administration of cisplatin during chemoradiation therapy can be recommended to a patient only if there are contraindications to high-dose chemotherapy.

Keywords:

oropharyngeal carcinoma
high-dose cisplatin
cumulative dose
radiomodification
chemotherapy regimens

Authors:

Stukan A.I.

Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar, Russia

Murashko R.A.

Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar, Russia

Bodnya V.N.

Department of Oncology with Course of Thoracic Surgery, Faculty for Postgraduate Training and Professional Retraining of Specialists, Kuban State Medical University, Ministry of Health of Russia, Krasnodar, Russia

Makarova Yu.M.

Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar, Russia

Vasilenko I.N.

Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar, Russia

Close metadata

References:

  1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N EnglJ Med. 2010;363(1):24-35. https://doi.org/10.1056/NEJMoa0912217
  2. Blanchard P, Hill C, Guihenneuc-Jouyaux C, Baey C, Bourhis J, Pignon JP. Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol. 2011;64(9):985-992. https://doi.org/10.1016/j.jclinepi.2010.10.016
  3. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-28. https://doi.org/10.1007/s00066-011-2217-7
  4. Ghosh-Laskar S, Kalyani N, Gupta T, Budrukkar A, Murthy V, Sengar M, Chaukar D, Pai P, Chaturvedi P, D’Cruz A, Agarwal J. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial. Head Neck. 2016;38(2):202-207. https://doi.org/10.1002/hed.23865
  5. Quon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A. Phase III study of radiation therapy with or without cisplatinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: An intergroup trial of the Eastern Cooperative Oncology Group (E2382). Int J Radiat Oncol Biol Phys. 2011;81(3):719-725. https://doi.org/10.1016/j.ijrobp.2010.06.038
  6. Melotek JM, Cooper BT, Koshy M, Silverman JS, Spiotto MT. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. J Otolaryngol Head Neck Surg. 2016;45(1):62. https://doi.org/10.1186/s40463-016-0175-x
  7. Brizel DM, Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol. 2006;24(17):2612-2617. https://doi.org/10.1200/JCO.2005.05.2829
  8. Gupta T, Agarwal JP, Laskar SG, Parikh PM, Cruz AKD, Dinshaw KA. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: A single-institution experience. Head Neck Oncol. 2009;1:17. https://doi.org/10.1007/978-3-319-14917-2_5
  9. Negi P, Kingsley PA, Srivastava H, Sharma SK. Three weekly versus weekly cisplatin as radiosensitizer in head and neck cancer: A decision dilemma. Asian Pac J Cancer Prev. 2016;17(4):1617-1623. https://doi.org/10.7860/JCDR/2017/24765.9293
  10. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high risk squamous-cell carcinoma of the head and neck. N EnglJ Med. 2004;350(19):1937-1952. https://doi.org/10.1056/NEJMoa032646
  11. Lu HJ, Yang CC, Wang LW, Chu PY, Tai SK, Chen MH, et al. Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer. Biomed Res Int. 2015;2015:1-7. https://doi.org/10.1007/s00066-015-0854-y
  12. Rawat S, Srivastava H, Ahlawat P, Pal M, Gupta G, Chauhan D, et al. Weekly versus three-weekly cisplatin based concurrent chemoradiotherapy as definitive treatment in head and neck cancer — where do we stand? Gulf J Oncolog. 2016;21:6-11. https://doi.org/10.1007/s12070-017-1210-6
  13. Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol. 2008;47(8):1513-1518. https://doi.org/10.1186/s40463-016-0175-x
  14. Geeta SN, Padmanabhan TK, Samuel J, Pavithran K, Kuriakose MA. Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. J Cancer Res Ther. 2006; 2(3):100-104. https://doi.org/10.1007/s00405-017-4687-4
  15. Kose F, Besen A, Sumbul T, Sezer A, Karadeniz C, Disel U, et al. Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: The Baskent Experience. Asian Pac J Cancer Prev. 2011;12(1): 185-188.
  16. Mitra D, Choudhury K, Rashid MA. Concurrent chemotherapy in advanced head and neck carcinoma - A prospective randomized trial. Bangaladesh J Otorhinolaryngol. 2011;17(2):88-95. https://banglajol.info/index.php/BJO/article/view/8847 https://doi.org/10.3329/bjo.v17i2.8847
  17. Azony AE, Sarhan AM, Hamouda WE, et al. Treatment outcome of concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. ZUMJ. 2012;18(5).
  18. Sahoo TK, Samanta DR, Senapati SN, Parida K. A comparative study on weekly versus three weekly cisplatinum based chemoradiation in locally advanced head and neck cancers. J Clin Diagn Res.2017;11(1):XC07-XC11. https://doi.org/10.7860/JCDR/2017/24765.9293
  19. Espeli V, Zucca E, Ghielmini M, Giannini O, Salatino A, Martucci F, et al. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. Oral Oncol. 2012;48(3):266-271. https://doi.org/10.1016/j.oraloncology.2011.10.005
  20. Uygun K, Bilici A, Karagol H, Caloglu M, Cicin I, Aksu G, et al. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2009;64:601-605. https://doi.org/10.1007/s00280-008-0911-7
  21. Tsan DL, Lin CY, Kang CJ, Huang SF, Fan KH, Lia CT, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012;7:215. https://doi.org/10.1186/1748-717X-7-215
  22. Fayette J, Molin Y, lavergne E, Montbarbon X, Sacadot S, Poupart M, et al. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma. Drug Des Dev Ther. 2015;9:6203-6210. https://doi.org/10.2147/DDDT.S81488
  23. Kang MH, Kang JH, Song HN, Jeong BK, Chai GY, Kang K, et al. Concurrent chemoradiation with low-dose weekly cisplatin in locally advanced stage IV head and neck squamous cell carcinoma. Cancer Res Treat. 2015;47(3):441-447. https://doi.org/10.4143/crt.2013.219
  24. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys. 2003;55:93-98. https://doi.org/10.1007/978-3-540-72314-1_7
  25. Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EEW, Halthore A, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2017;7(4):246-253. https://doi.org/10.1016/j.prro.2017.02.002
  26. Radiation Therapy Oncology Group. Radiation therapy with cisplatin, docetaxel, or cetuximab after surgery in treating patients with stage III-IV squamous cell head and neck cancer. https://www.clinicaltrials.gov/ct2/show/NCT01810913 Accessed November 1, 2016
  27. Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol. 2013;14(3):257-264. https://doi.org/10.1016/S1470-2045(13)70011-1
  28. Cohen EEW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735-2743. https://doi.org/10.1200/JCO.2013.54.6309
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.